financetom
Business
financetom
/
Business
/
Mortgage Company Guild Agrees to $1.3 Billion Go-Private Deal; Shares Jump
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mortgage Company Guild Agrees to $1.3 Billion Go-Private Deal; Shares Jump
Jun 18, 2025 10:37 AM

01:18 PM EDT, 06/18/2025 (MT Newswires) -- Guild Holdings ( GHLD ) said Wednesday that a fund managed by Bayview Asset Management has agreed to acquire the outstanding shares of the mortgage company that it does not already own in a roughly $1.3 billion all-cash deal.

Guild stockholders will receive $20 for each share held. The consideration represents a roughly 56% premium to the company's unaffected closing stock price May 23, the last trading day before a filing by Bayview indicated its potential interest in a transaction with the company.

Guild shares were up nearly 26% in Wednesday afternoon trade.

Upon the deal's completion, Guild will operate as a privately held independent entity in partnership with Bayview affiliate and mortgage servicer Lakeview Loan Servicing.

"Expanding the Guild relationship with Lakeview creates one of the strongest and most compelling mortgage origination and servicing ecosystems in the nation," Guild Chief Executive Terry Schmidt said. "Our expertise in distributed retail origination, retained servicing, and the customer-for-life balanced business model makes this a complementary partnership that has powerful potential for growth and innovation."

McCarthy Capital Mortgage Investors has provided a written consent to approve the deal, Guild said, with no further action required by other stockholders.

The transaction is expected to close in the fourth quarter. Guild executives and management team will remain in place, while there will be no "material change" to the company's brand or business operations, it said.

The company said its board plans to authorize a special cash dividend of up to $0.25 a share in 2025.

Price: 19.75, Change: +4.03, Percent Change: +25.64

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fiera Capital Q3 revenue slightly misses estimates
Fiera Capital Q3 revenue slightly misses estimates
Nov 13, 2025
Overview * Fiera Capital ( FRRPF ) Q3 revenue slightly misses analyst expectations * Adjusted EPS for Q3 meets analyst estimates * Company achieved positive net organic growth in AUM, driven by new relationships Outlook * Company did not provide specific guidance for future quarters or full year Result Drivers * NET ORGANIC GROWTH - Positive net organic growth of...
Xilio Therapeutics' Q3 collaboration revenue rises
Xilio Therapeutics' Q3 collaboration revenue rises
Nov 13, 2025
Overview * Xilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-year * Net loss for Q3 widens to $16.3 mln from $14.0 mln year-over-year * Company anticipates cash runway into Q1 2027 Outlook * Xilio plans to submit IND for XTX501 in mid-2026 * Company anticipates cash runway into Q1 2027 * Xilio seeks partner for vilastobart...
Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
Palatin fiscal Q1 revenue hits $8.8 mln, net income $4.7 mln
Nov 13, 2025
Overview * Palatin fiscal Q1 2026 revenue rises to $8.8 mln, driven by Boehringer Ingelheim agreement * Company reports fiscal Q1 net income of $4.7 mln, reversing a loss from last year * Palatin ( PTN ) completes $18.2 mln public offering, regains NYSE American compliance Outlook * Company plans IND submission and Phase 1 trial for PL7737 in first...
HLS Therapeutics Narrows Q3 Loss as Vascepa Scripts Climb
HLS Therapeutics Narrows Q3 Loss as Vascepa Scripts Climb
Nov 13, 2025
07:43 AM EST, 11/13/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) said Thursday that third-quarter net loss narrowed slightly as revenue rose. Net loss improved to US$3.92 million, or $0.12 per share, from a loss of $4.84 million, or $0.15 per share in the prior year period. Revenue decreased 4% to $13.5 million, primarily due to lower Clozaril Canada...
Copyright 2023-2026 - www.financetom.com All Rights Reserved